Sangamo Therapeutics Inc (NASDAQ:SGMO) does about 2.41M shares in volume on a normal day but saw 2278588 shares change hands in Tuesday trading. The company now has a market cap of 106.09M USD. Its current market price is $0.52, marking an increase of 2.12% compared to the previous close of $0.51. The 52 week high reached by this stock is $1.78 whilst the lowest price level in 52 weeks is $0.29.
Sangamo Therapeutics Inc (SGMO) has a 20-day trading average at $0.5607 and the current price is -70.74% off the 52-week high compared with 78.94% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.7967 and its 200-day simple moving average is $0.7238. If we look at the stock’s price movements over the week, volatility stands at 11.53%, which decreases to 10.47% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 39.24 to suggest the stock is neutral.
The consensus objective for the share price is $3.50, suggesting that the stock has a potential upside of 85.14% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on November 03, 2023 when RBC Capital Mkts downgraded the stock to “Sector Perform” and issued a price target of between $6 and $2. BofA Securities also downgraded the stock to “Underperform” from Neutral on April 28, 2023 at a price target of $5-$1.50. Wedbush upgraded its price target at $16.
Sangamo Therapeutics Inc (SGMO) stock is down -3.89% over the week and -25.90% over the past month. Its price is -4.12% year-to-date and -68.62% over the past year.
The stock last released its quarterly earnings report for quarter ended 12/31/2023, with the company’s earnings per share (EPS) of 0.12 above consensus estimates by 0.45. The company’s next earnings report forecasts estimating quarterly EPS at -0.21 and -0.5 for whole year. Expected sales for next quarter are $8.24M, which analysts say will come at $45.88M for the current fiscal year and next year at $79.01M. In addition, estimates put the company’s current quarterly revenue at an average of $6.65M.
To reach the target analysts have set, the stock logically needs to grow 85.14 percent from here.
The company has a return on investment of -221.50% and return on equity of -136.48%. The beta has a value of 1.39. Price to book ratio is 1.12 and price to sales ratio is 0.60.
